ZLNA — Zelluna ASA Share News
0.000.00%
Last trade - 00:00- NOK544.15m
- NOK451.38m
Brief: Ultimovacs Q4 Operating Expenses NOK 121 Million
Brief: Ultimovacs Announces Agreement To Combine Its Business With Zelluna Immunotherapy And Intention To Launch Fully Committed Private Placement
Brief: Ultimovacs Q3 Operating Loss Narrows To NOK 28.8 Mln
Brief: Ultimovacs Q3 Operating Expenses NOK 28.8 Million
Brief: Ultimovacs Announces Publication Of Phase II Focus Trial Results On Medrxiv
Brief: Ultimovacs Expects Current Financial Resources Will Sustain Operations To Q4, 2025
Brief: Ultimovacs Q2 Operating Expenses NOK 45.3 Million
Brief: Ultimovacs Says Topline Results Are Expected In First Half Of 2025
Brief: Ultimovacs Provides Update From Phase I Study In Malignant Melanoma
Brief: Ultimovacs Sees Cash Burn Rate of About NOK 15 Mln/Quarter Towards End-2025
Brief: Ultimovacs Q1 Operating Expenses NOK 28.6 Million
Brief: Ultimovacs Implements Operational Adjustments To Support Continuous Advancement Of The Uv1 Vaccine Phase Ii Program
Brief: Ultimovacs To Not Distribute Dividend
Brief: Ultimovacs Closely Related Parties Sell Shares in Co
Brief: Ultimovacs Closely Related Parties Sell Shares
Brief: Watrium Sells Stake In Ultimovacs
Brief: Canica Sells 1,000,000 Shares In Ultimovacs
Brief: Ultimovacs Says Primary And Secondary Endpoints Of Initium Study Not Met
Brief: Ultimovacs Announces Publication Of Results From Nipu Phase Ii Trial With Uv1 Vaccination In Mesothelioma In European Journal Of Cancer